Northbrook, Illinois-based Kalohexis, Inc. — a clinical-stage biotechnology company targeting the melanocortin receptor system for obesity and cancer cachexia — confidentially submitted a draft registration statement via a Form S-1 filing to the US Securities and Exchange Commission on July 7, 2026, to hold an initial public offering of its common stock. The filing brings another clinical-stage obesity developer to the IPO pipeline, with Kalohexis differentiated by a non-GLP-1 oral mechanism targeting the melanocortin receptor system.
The share count, price range, and exchange listing have not been determined. The offering is expected to proceed after the SEC completes its review, and no bookrunners, crossover investors, or concurrent private placements were disclosed. Kalohexis was spun out of Endevica Bio in March 2026, approximately four months before the confidential submission.
Kalohexis was spun out of Endevica Bio, a Northbrook, Illinois-based private biotech focused on melanocortin receptor peptides, to independently advance a pipeline of therapeutic peptides targeting central melanocortin-3 and -4 receptors (MC3R/MC4R). The company's lead asset, 710GO, is an oral dual MC3R/MC4R agonist in Phase I development for general obesity, with first patients dosed in May 2026 in Australia. Its second program, mifomelatide (formerly TCMCB07), is a dual MC3R/MC4R antagonist in Phase II development for cachexia in patients with advanced cancers, with the trial initiated in Q2 2025.